Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study.

Journal of cardiovascular electrophysiology - 1 Nov 2007

Schimpf Rainer, Veltmann Christian, Giustetto Carla, Gaita Fiorenzo, Borggrefe Martin, Wolpert Christian

Abstract excerpt

INTRODUCTION: Quinidine has been evaluated in patients with a short QT-1 syndrome caused by an IKr gain-of-function mutation of HERG. Recently, in vitro data with disopyramide showed an even stronger effect on the N588K mutant current. The aim of the present study was to test the in vivo effects of disopyramide in patients with short QT-1 syndrome caused by a N588K mutation in HERG. METHODS AND RESULTS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diarrhea
Share to Anti-Arrhythmia Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Arrhythmias, Cardiac

Share to ERG1 Potassium Channel

Share to Ether-A-Go-Go Potassium Channels

Share to Exercise Test

Share to Pilot Projects

Share to Quinidine

Source

Identifiers

PMID: 17711440
DOI: 10.1111/j.1540-8167.2007.00925.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study.PMID 17711440Read ↗

Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome.Semantic proximity Read ↗

Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG.Semantic proximity Read ↗

In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles.Semantic proximity Read ↗

QT interval prolongation and cardiac risk assessment for novel drugs.Semantic proximity Read ↗

Molecular predictors of drug-induced prolongation of the QT interval.Semantic proximity Read ↗

Acquired QT interval prolongation and HERG: implications for drug discovery and development.Semantic proximity Read ↗

hERG potassium channels and cardiac arrhythmia.Semantic proximity Read ↗

[HERG K+ channel, the target of anti-arrhythmias drugs].Semantic proximity Read ↗

Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.Semantic proximity Read ↗

Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.Semantic proximity Read ↗

Drug-induced torsades de pointes: the evolving role of pharmacogenetics.Semantic proximity Read ↗

Slow delayed rectifier potassium current blockade contributes importantly to drug-induced long QT syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.